What are the clinical trial results of Obeticholic acid?

Obeticholic acid is a selective farnesoid The original intention of its development is to provide new treatment options for patients who cannot tolerate or have insufficient response to ursodeoxycholic acid (UDCA). According to overseas multi-center clinical studies, OCA has demonstrated sustained and significant efficacy in improving hepatobiliary function and reducing cholestasis-related indicators.

In a 12-month randomized, double-blind controlled study, the study subjects were adult patients with PBC aged 29 to 86 years old (average age 56 years old). These patients still did not achieve the desired effect after 12 months of using UDCA, or discontinued UDCA due to intolerance. The primary endpoint of the study was based on three composite criteria: patients needed to have alkaline phosphatase (ALP) drop to less than 1.67 times the upper limit of normal and a decrease of at least 15% from baseline, while total bilirubin levels remained within the upper limit of normal. The results of the study showed that significantly more patients who received OCA achieved the composite endpoint, and liver function indicators continued to improve compared with those who received UDCA alone.

The long-term extension study (OLE, open-label extension trial) followed 193 patients for 5 years. All enrolled patients received 5 mg of OCA daily for the first three months and were titrated based on individual tolerance and response. The results showed that most patients maintained stable efficacy during long-term use and continued to meet the composite endpoint criteria. It is worth emphasizing that the data of this study continued from the double-blind phase, verifying that the efficacy of OCA can be maintained for a long time and has good safety. Overseas scholars pointed out that this long-lasting improvement in biochemical reactions is closely related to the continuous regulation of bile acid metabolism, suggesting that FXR agonists may play a profound role in delaying liver fibrosis.

However, this study also has certain limitations. The maximum dose of OCA specified in the study is 10 mg, which excludes subjects who take more than 10 mg daily, so the efficacy and risks of higher doses cannot be fully evaluated. In addition, this analysis is a post hoc exploratory study. Although the results have clinical reference significance, more prospective trials are still needed to verify its conclusions. Foreign hepatology experts believe that the impact of OCA on the progression of cirrhosis, improvement of quality of life, and long-term survival rate should be further evaluated through multi-center, long-term randomized studies in the future.

Although there are certain limitations,OCA is still recognized as the only add-on treatment for PBC with more than six years of clinical trials and real-world experience. In real-world data from Europe and the United States, after patients continued to use OCA, not only did their liver enzyme indicators continue to decline, but they also showed a trend of slowing down the degree of liver fibrosis. Some long-term follow-up studies even suggest that early use of OCA may help delay the transformation of PBC into decompensated cirrhosis.

Taken together, the clinical trial results of obeticholic acid reflect its core value as an FXR agonist in the regulation of bile acid metabolism. It improves bile outflow, inhibits inflammatory response, and reduces liver fibrosis through multi-target mechanisms, thereby bringing lasting biochemical and clinical benefits to PBC patients. With the accumulation of long-term research data, OCA's position in the global liver disease treatment field has become increasingly consolidated, and it has also provided a new direction for future treatment exploration of metabolic liver diseases such as non-alcoholic steatohepatitis (NASH).

Reference materials:https://en.wikipedia.org/wiki/Obeticholic_acid